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In mammals, peroxisomes perform crucial functions in cellular metabolism, signaling
and viral defense which are essential to the viability of the organism. Molecular
cues triggered by changes in the cellular environment induce a dynamic response
in peroxisomes, which manifests itself as a change in peroxisome number, altered
enzyme levels and adaptations to the peroxisomal morphology. How the regulation
of this process is integrated into the cell’s response to different stimuli, including the
signaling pathways and factors involved, remains unclear. Here, a cell-based peroxisome
proliferation assay has been applied to investigate the ability of different stimuli to
induce peroxisome proliferation. We determined that serum stimulation, long-chain
fatty acid supplementation and TGFβ application all increase peroxisome elongation,
a prerequisite for proliferation. Time-resolved mRNA expression during the peroxisome
proliferation cycle revealed a number of peroxins whose expression correlated with
peroxisome elongation, including the β isoform of PEX11, but not the α or γ isoforms.
An initial map of putative regulatory motif sites in the respective promoters showed a
difference between binding sites in PEX11α and PEX11β, suggesting that these genes
may be regulated by distinct pathways. A functional SMAD2/3 binding site in PEX11β
points to the involvement of the TGFβ signaling pathway in expression of this gene and
thus peroxisome proliferation/dynamics in humans.
Keywords: peroxisomes, organelle dynamics, transcriptional regulation, peroxin, PEX11, transforming growth
factor beta
Abbreviations: AA, arachidonic acid; ABCD, ATP-binding cassette sub-family D; ACAA1, acetyl-CoA acyltransferase
1; ACOX1, acyl-CoA oxidase 1; AGPS, alkylglycerone phosphate synthase; CRAT, carnitine O-acetyltransferase; CROT,
carnitine O-octanoyltransferase; DHA, docosahexaenoic acid; DRP1, dynamin-related protein 1; EHHADH, enoyl-CoA
hydratase and 3-hydroxyacyl-CoA dehydrogenase; FAR1, fatty acyl-CoA reductase 1; FBS, fetal bovine serum; FIS1,
mitochondrial fission 1 protein; GNPAT, glyceronephosphate O-acyltransferase; LA, linoleic acid; MFF, mitochondrial
fission factor; mTOR, mammalian target of rapamycin; OA, oleic acid; PA, palmitic acid; PEX, peroxisome biogenesis
factor (peroxin); PGC1, PPAR gamma coactivator 1; PMP, peroxisomal membrane protein; PPAR, peroxisome proliferator
activated receptor; PPRE, peroxisome proliferator response element; PUFA, polyunsaturated fatty acid; SMAD, small
worm phenotype/mothers against decapentaplegic homolog; TGFβ, transforming growth factor β; VLCFA, very-long-chain
fatty acid.
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INTRODUCTION
Peroxisomes represent crucial subcellular compartments that are
essential for human life and health. They perform key roles
in cellular lipid metabolism, for example the breakdown and
detoxification of fatty acids by α- and β-oxidation, and the
synthesis of ether-phospholipids (e.g., plasmalogens, which are
enriched in myelin sheaths), bile acids and polyunsaturated
fatty acids (e.g., DHA) (Wanders, 2013a). Peroxisomes also
contribute to hydrogen peroxide metabolism, cellular redox
balance and redox signaling (Fransen and Lismont, 2018).
Defects in peroxisome metabolic functions or biogenesis result
in severe disorders with developmental and neurological defects
(Wanders, 2013b; Braverman et al., 2016).
Peroxisomes are remarkably dynamic organelles, which
respond to stimulation by adapting their morphology,
abundance, and metabolic functions according to cellular needs.
New peroxisomes can form from pre-existing peroxisomes
by membrane growth and division, which results in their
multiplication/proliferation (Schrader et al., 2016). Growth
and division in mammalian cells follows a well-defined
multi-step process of morphological alterations including
elongation/remodeling of the peroxisomal membrane,
constriction and recruitment of division factors (e.g., the
adaptor proteins MFF, FIS1), and final membrane scission (by
the dynamin-related GTPase DRP1) (Schrader et al., 2016). The
membrane shaping peroxisomal membrane protein PEX11β
contributes to multiple steps of peroxisomal growth and division
including membrane deformation and elongation (Delille et al.,
2010; Opaliński et al., 2011), recruitment of MFF and FIS1 to
constriction sites (Koch et al., 2005; Koch and Brocard, 2012;
Itoyama et al., 2013), and activation of DRP1 for membrane
fission (Williams et al., 2015). Besides PEX11β, humans express
two additional PEX11 isoforms, PEX11α and PEX11γ, but their
exact functions are unclear and may differ, given that both
isoforms cannot or only partially complement loss of PEX11β
(Ebberink et al., 2012). So far, only patients with a defect in
the β isoform of PEX11 have been identified, who present with
enlarged peroxisomes, congenital cataracts, progressive hearing
loss, short stature and neurological abnormalities (Ebberink
et al., 2012; Taylor et al., 2017; Tian et al., 2019).
Although our understanding of the mechanisms by which
peroxisomes proliferate is increasing, we have limited knowledge
of how peroxisome biogenesis and division/multiplication is
regulated by stimuli. In plants, it has been suggested that
peroxisome proliferation can be stimulated by light, due to an
increase in PEX11b transcription regulated by the transcription
factors HYH and FHA3 (Desai and Hu, 2008; Desai et al.,
2017). However, relatively little is known about how extracellular
signals feed into peroxisome biogenesis in mammals and
especially in humans. The best characterized regulatory pathway
in mammals is the peroxisome proliferator-activated receptor
(PPAR)-dependent pathway (Kliewer et al., 1992; Schrader et al.,
2012b). PPARs are a family of transcription factors which
modulate transcription of target genes in response to a variety
of structurally diverse ligands, including xenobiotic chemicals
called peroxisome proliferators, and both natural and synthetic
fatty acids (Rakhshandehroo et al., 2010). PPARα is expressed
predominantly in the liver, heart and brown adipose tissue,
and is a major activator of fatty acid oxidation pathways (la
Cour Poulsen et al., 2012). PPARγ is most highly expressed
in white and brown adipose tissue, and functions as a master
regulator of adipogenesis as well as a potent modulator of whole-
body lipid metabolism and insulin sensitivity (Tontonoz and
Spiegelman, 2008; Dubois et al., 2017; Kersten and Stienstra,
2017). PPARβ/δ is the most poorly characterized isoform, but
is ubiquitously expressed and is thought to be important
in lipid and cholesterol metabolism (Grygiel-Górniak, 2014).
Upon ligand binding, PPARs hetero-dimerise with their binding
partner, the 9-cis-retinoic acid receptor, RXRα, and bind to
specific cis-acting DNA response elements known as PPRE,
to initiate gene transcription. ChIP-seq analysis in human
hepatoblastoma HepG2 cells revealed PPARα-occupied PPREs in
genes encoding for peroxisomal enzymes such as ACOX1 (van
der Meer et al., 2010), suggesting that their expression is regulated
by PPARα.
PPARα agonists can significantly increase peroxisome number
and the levels of fatty acid β-oxidation enzymes (Lazarow and
De Duve, 1976; Schrader et al., 2016), but whilst rodents usually
respond with a strong peroxisome proliferation phenotype, the
effect in humans is very mild (Lawrence et al., 2001; Islinger et al.,
2010). Although there is evidence for a functional PPRE in the
promoter region of the PEX11α gene in both mouse (Shimizu
et al., 2004) and human (Rakhshandehroo et al., 2010), there is
little information so far on transcriptional regulation of other
PEX genes in mammals, and especially humans. For example,
there is currently no evidence for up-regulation of human
PEX11β, as a key factor in peroxisome proliferation, following
stimulation with PPARα agonists. In line with this, there is
growing evidence that PPAR-independent pathways exist which
can be activated by extracellular signals such as ROS and growth
factors (Schrader and Fahimi, 2006; Bagattin et al., 2010; Fransen
et al., 2012). Although the involvement of a variety of regulatory
pathways in controlling transcription of peroxisome proliferation
related genes under different conditions has been suggested, it
is currently unclear how up-regulation of peroxisomal genes is
linked to up-regulation of peroxisome proliferation.
Several studies have implicated the growth factor TGFβ
in the regulation of peroxisomes, and while it has been
suggested to both increase (Schrader et al., 1998a) and
decrease (Oruqaj et al., 2015) peroxisome biogenesis under
different conditions, the direct targets involved in this process
are unclear. The TGFβ family consists of multifunctional
proteins that regulate a diverse range of processes during
development and tissue homeostasis, such as cell proliferation,
apoptosis, autophagy, inflammation, angiogenesis, and epithelial-
to-mesenchymal transition (Kitisin et al., 2007; Nagaraj and
Datta, 2010; Horbelt et al., 2012; Massagué, 2012). There
are three known isoforms of TGFβ (TGFβ1, TGFβ2, and
TGFβ3) expressed in mammalian tissues; they contain highly
conserved regions but are different in several amino acid
sequences. All of these isoforms function through the same
receptor signaling pathways (Horbelt et al., 2012). TGFβ isoforms
bind to receptors at the cell surface, and recruit two type I
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receptors and two type II receptors forming a tetrameric complex
(Massagué, 2012). Activated TGFβ superfamily receptors induce
a phosphorylation cascade, from receptor phosphorylation to
subsequent phosphorylation and activation of downstream
signal transducer R-SMAD transcription factors (receptor-
activated SMADs, including SMAD2/3) (Hill, 2016; Miyazawa
and Miyazono, 2017). Phosphorylated R-SMADs form a
hetero-oligomeric (often trimeric) complex with SMAD4.
This R-SMAD/SMAD4 complex is imported into the nucleus
where it regulates the expression of target genes by direct
binding to specific motifs in the target gene promoter and/or
through interaction with transcriptional cofactors in a cell-
type-specific manner (Hariharan and Pillai, 2008; Kamato
et al., 2013). SMAD target genes include the transcription
factors PGC-1α and PPARγ, classically thought to regulate
peroxisome proliferation, with elevated TGFβ signaling leading
to systemic insulin resistance and hepatic steatosis through
decreased expression of these target proteins (Yadav et al.,
2011; Sohn et al., 2012). Additionally, PPARα may act
upstream of TGFβ-dependent gene transcription, with PPARα
ligands reported to decrease TGFβ-induced integrin expression
by inhibiting SMAD4 complex formation (Kintscher et al.,
2002), suggesting a complex interplay between TGFβ signaling
and PPAR function.
Since deficiencies in peroxisome proliferation have been
associated with a variety of disease states, including liver diseases
and neurological dysfunction, as well as cellular aging (Cimini
et al., 2009; Titorenko and Terlecky, 2011; Schrader et al.,
2014; Passmore et al., 2020), a clearer understanding of the
mechanisms and signaling pathways that control peroxisome
plasticity could allow for modulation of peroxisome abundance
to improve cellular function in health and disease. In this study,
we aimed to identify novel signaling pathways and associated
factors involved in peroxisome dynamics in humans, using a cell-
based assay to investigate different stimuli and their ability to
induce peroxisome proliferation. Examination of mRNA levels
during peroxisome proliferation suggested differential regulation
of peroxisomal genes correlating with their cellular function.
Specifically, we identified differential regulation and functions
of the PEX11 isoforms PEX11α and PEX11β in peroxisome
dynamics. A functional SMAD2/3 binding site in the promoter
of PEX11β suggests a novel link between the canonical TGFβ
signaling pathway and the induction of peroxisome proliferation,
potentially via PEX11β expression, providing new insights into
the regulation of peroxisome dynamics in humans.
MATERIALS AND METHODS
Plasmids and Antibodies
For cloning of PEX11β promoter regions, the candidate promoter
region (1,302 bp for the wild type and 1,296 bp for the
mutant lacking the SMAD2/3 binding site) of human PEX11β
was synthesized (Eurofins Genomics) and then cloned into
the pGL3-basic vector upstream of the firefly luciferase coding
sequence (#E1751, Promega). The pGL3-basic vector without a
promoter was used as a negative control. pRL-TK vector (#E2231,
Promega) was used as internal control vector to normalize
luciferase activities. See Supplementary Table 1 for details of
plasmids used in this study, Supplementary Table 2 for plasmids
generated in this study and Supplementary Table 3 for details of
qPCR primers used. All constructs produced were confirmed by
sequencing (Eurofins Genomics). Details of all antibodies used in
this study can be found in Supplementary Table 4.
Cell Culture and Cell-Based Peroxisome
Proliferation Assay
For routine culture, HepG2 cells (human hepatoblastoma
cells, HB8065; ATCC) were maintained in Minimal Essential
Medium (MEM; Life Technologies) supplemented with 10%
FBS, (100 U/ml penicillin and 100 µg/ml streptomycin) at
37◦C in a 5% CO2-humidified incubator. COS-7 (African green
monkey kidney cells, CRL-1651; ATCC), PEX11β-deficient skin
fibroblasts (Ebberink et al., 2012) and PEX11 KO HeLa cells
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM;
Life Technologies) supplemented as above. COS-7 cells were
transfected using diethylaminoethyl (DEAE)-dextran (Sigma-
Aldrich) as described (Bonekamp et al., 2010). For stimulation
experiments, HepG2 cells were cultured in serum-free MEM
with N1 supplement [Sigma: 0.5 mg/ml recombinant human
insulin, 0.5 mg/ml human transferrin (partially iron-saturated),
0.5 µg/ml sodium selenite, 1.6 mg/ml putrescine, and 0.73 µg/ml
progesterone] containing 0.25% BSA. For morphological analysis
of peroxisomes, 70,000/cm2 HepG2 cells were seeded on
collagen (Serva)-coated glass coverslips. Compounds/inhibitors
were added 6 h after seeding and cells were processed for
immunofluorescence at different time points after incubation
(as indicated in Figures). Fatty acid stocks (Sigma-Aldrich)
were dissolved in ethanol. WY-14643 (#C7081), Troglitazone
(#T2573), GW9962 (#M6191), Rapamycin (#R0395), LY2109761
(#SML2051), and SB431542 (#616461) were obtained from
Sigma-Aldrich. Recombinant human TGFβ was obtained from
R&D Systems (#240-B). Stimulation with 10% FBS served as a
positive control for peroxisome elongation/proliferation.
Generation of PEX11-Deficient HeLa
Cells by CRISPR-Cas9
For each PEX11 gene, two different sgRNA guide sequences
targeting an exon of PEX11α, PEX11β, or PEX11γ were
selected using the CRISPR Design Tool1 (Ran et al., 2013)
(Supplementary Table 5). Complementary guide oligos
were annealed and subsequently cloned into the pX458
[-pSpCas9(BB)-2A-GFP] plasmid (Addgene). Cells were
transfected in six-well plates with 2 µg plasmid containing
sgRNA targeting PEX11α, PEX11β or PEX11γ (jetPRIME
DNA Transfection). Single GFP-positive cells were sorted by
fluorescence-activated cell sorting into 96-well plates (SH800 Cell
Sorter, Sony Biotechnology) as described (Ran et al., 2013). After
∼4 weeks, DNA was isolated from multiple expanded single
colonies, and the targeted exon of the PEX11 genes were PCR
amplified using Phire Hot Start II DNA Polymerase (Thermo
1http://crispr.mit.edu/
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 October 2020 | Volume 8 | Article 577637
fcell-08-577637 October 18, 2020 Time: 19:3 # 4
Azadi et al. Regulation of Human Peroxisome Dynamics
Fisher Scientific) and subsequently Sanger sequenced to confirm
clonal populations with heterozygous mutations in PEX11α,
PEX11β, and PEX11γ (Supplementary Table 5).
Transfection and Dual Luciferase
Reporter Assay
2 × 105 HepG2 cells/well were seeded the day before transfection
in 6-well plates in 1.5 ml complete growth MEM. 1 µg of
the desired pGL3 vector DNA and 40 ng pRL-TK vector DNA
(ratio 25:1) was transfected per well using Lipofectamine 3000
(Invitrogen) according to instructions.
48 h after transfection, cells were seeded in MEM/N1 media in
96 cell plates. 6 h after seeding, cells were treated with TGFβ, FBS
or left untreated and were incubated for 24 h prior to performing
the Dual-Luciferase Reporter assay (Promega, #E1910) with a
MicroLumat Plus LB 96V luminometer (Berthold Technologies),
according to manufacturer’s instructions. Luminescence was
measured for 10 s, and each reaction was measured three times.
For analysis, Firefly luciferase activities were normalized to
Renilla luminescence in each well.
RNA Isolation and Quantitative PCR
Total RNA was prepared from HepG2 cells with the NucleoSpin
RNA Kit (#740955.50; Macherey-Nagel) and DNA was removed
by on-column digestion with rDNase. cDNA was synthesized
from 2 µg RNA with random hexamer primers using the High-
Capacity RNA-to-cDNA Kit (#4368813; Applied Biosystems) and
diluted 10-fold in sterile H20. The real-time qPCR reaction
was performed on a Roche LightCycler LC480 instrument in
duplicates using 10 ng cDNA, 7.5 pmol forward and reverse
primers, and the 2× KAPA SYBR FAST qPCR Mastermix
(#KK4601; KAPA Biosystems). Thermal cycling was carried out
with a 5 min denaturation step at 95◦C, followed by 45 three-step
cycles: 10 s at 95◦C, 10 s at 60◦C, and 10 s at 72◦C. Melt curve
analysis was carried out to confirm the specific amplification
of a target gene and absence of primer dimers. Relative mRNA
amount was calculated using the comparative threshold cycle
method. 18S rRNA was used as the invariant control.
Immunofluorescence and Microscopy
Cells were processed for immunofluorescence 24–48 h after
transfection. Cells grown on collagen-coated glass coverslips
were fixed for 20 min with 4% (w/v) para-formaldehyde in
PBS (pH 7.4), permeabilized with 0.2% (w/v) Triton X-100 for
10 min and blocked with 1% BSA for 10 min. Blocked cells were
sequentially incubated with primary and secondary antibodies for
1 h in a humid chamber. Coverslips were washed with ddH2O
to remove PBS and mounted with Mowiol medium (containing
25% n-propyl-gallate as anti-fading reagent) on glass slides. All
immunofluorescence steps were performed at room temperature
and cells were washed three times with PBS, pH 7.4 between each
individual step. Cell imaging was performed using an Olympus
IX81 microscope equipped with an UPlanSApo 100×/1.40 oil
objective (Olympus). Digital images were taken with a CoolSNAP
HQ2 CCD camera. Representative images only were adjusted for
contrast and brightness using the Olympus Soft Imaging Viewer
software (Olympus) and MetaMorph 7 (Molecular Devices).
Promoter Analysis
For each PEX11 isoform gene, regions 10kb upstream of the
start codon were scanned base-pair by base-pair for regulatory
elements using the GimmeMotif programme (van Heeringen
and Veenstra, 2010). To obtain transcription factor binding
site motifs to search for, position weight matrices representing
the DNA binding preferences of 700 transcription factors were
imported from the JASPAR CORE database2. Bona fide binding
sites in the regulatory region for each chosen gene were defined
as having a higher than 89% potential match to a JASPAR motif.
Binding efficiency to SMAD2/3 motifs was calculated relative
to the JASPAR position weight matrix consensus sequence (ID
MA0513.1). In order to eliminate non-active motif binding sites
based on chromosome structure, the presence of H3K4me3,
H3K36me3, H3K27ac histone marks and absence of H3K27m3
near the potential motif was checked with the USCS Genome
Browser as indicators of transcriptionally active sites in HepG2
cells. The ENCODE database of transcription factor binding
tracks was used to exclude transcriptionally silent sites in each
gene (those with a score of <500 out of 1000 for ChIP-seq
evidence of transcription factor binding).
Quantification and Statistical Analysis of
Data
For quantitative analysis of peroxisome morphology, 100–200
cells per coverslip were examined and categorized possessing
elongated/tubular (>2 µm in length) or spherical peroxisomes
(0.3–2 µm; including rod-shaped peroxisomes) (Schrader et al.,
1996). For quantification of peroxisome number, images were
acquired in the focal plane of the nucleus, and peroxisome
number per cell was determined using an in-house ImageJ
macro (Schneider et al., 2012; Passmore et al., 2020) based on
the ‘Analyze Particles’ function. Usually, three coverslips per
preparation were analyzed, and three independent experiments
were performed. Statistical analyses were performed using
GraphPad Prism 5 software. Data are presented as means ± SD.
Two-tailed unpaired t-tests (for experiments with two groups)
or one-way ANOVAs with appropriate post hoc tests (for
experiments with three or more groups) were used to determine
statistical differences against control values (see Figure Legends
for details). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ns, non-
significant.
RESULTS
Validation of a Cell-Based Peroxisome
Proliferation Assay
Expansion of the peroxisomal membrane is the first in a sequence
of morphological changes that occur during peroxisomal growth
and division in mammalian cells (Schrader et al., 2016). In human
2http://jaspar.genereg.net/
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hepatoblastoma HepG2 cells, elongated or tubular peroxisomes
increase in number for approximately 24 h after seeding; the
number of tubular peroxisomes decreases after this time point as
fission occurs and most of the cells show spherical peroxisomal
forms (Schrader et al., 1996). This membrane growth and
subsequent fission contributes to the multiplication/proliferation
of peroxisomes under conditions of cellular growth. In order
to characterize and measure the progression of peroxisome
proliferation in HepG2 cells, we have established a cell-
based proliferation assay to measure synchronous peroxisome
dynamics (Figure 1). Alterations in peroxisome morphology
under different culture conditions were quantified over time by
immunofluorescence microscopy, staining for the peroxisomal
membrane protein PEX14 (Nguyen et al., 2006; Grant et al.,
2013). Under standard culture conditions (MEM with 10% FBS
[MEM/FBS]), the number of tubular peroxisomes increased
in a time-dependent manner in HepG2 cells seeded at a
defined density, as previously reported (Schrader et al., 1996).
In cells cultured in defined serum-free media (MEM with N1
supplement [MEM/N1]), however, the majority of peroxisomes
remained spherical after 24 h of culture (Figures 1A,B),
creating a ‘basal’ state from which peroxisome tubulation
could be induced and measured. By synchronizing peroxisomes
in a spherical form in this way, a change in peroxisome
morphology could be monitored to determine modulators of
peroxisome proliferation.
To validate that our assay system could be used to detect
and follow changes in peroxisome morphology in response
to environmental stimuli, HepG2 cells were incubated for
6 h in MEM/N1, where cells display spherical and rod-
shaped peroxisome morphologies, then exposed to 10% FBS for
24 h (‘serum stimulation’). Peroxisome morphology was again
assessed by PEX14 immunofluorescence. Serum stimulation
increased the proportion of cells with tubular peroxisomes to
more than 80% (Figure 1B), whereas peroxisomes remained
predominantly spherical in cells kept in serum-free medium.
Furthermore, after 48 h, the number of peroxisomes per
cell was 60% higher in serum-stimulated cells compared to
those cultured in MEM/N1 (Figure 1C). This confirms that
elongated peroxisomes, which peak in number after 24 h,
divide by fission and contribute to peroxisome proliferation.
These observations indicate that peroxisomal growth and
division is reduced under serum-free culture conditions, and
therefore that the peroxisomal compartment is responsive to
serum stimulation.
To test if cellular growth in MEM/N1 is comparable to
standard growth conditions, we determined and compared
cellular growth over time. Cells cultured in MEM/N1 display
slightly lower growth rates when compared to cells cultured in
MEM/FBS (Supplementary Figure 1). However, the cells are
actively proliferating and an exponential increase in cell density
arises. It should, however, be noted that the cells appear smaller
and are not as extensively spread as HepG2 cells grown under
standard conditions.
With this cell-based assay, we have established an inducible
system to dissect the distinct phases of peroxisome proliferation
in a synchronous manner, and test different stimuli and their
effect on peroxisome dynamics and proliferation in a quantitative
fashion. To verify the assay, we first applied arachidonic acid
(AA) [C20:4 (ω-6)] as a positive control. This PUFA serves as
a precursor for the synthesis of a number of biologically active
lipid mediators and has been reported to induce peroxisome
elongation/proliferation in a previous study (Schrader et al.,
1998a). Indeed, our results show that 50 µM AA causes a
prominent increase in the percentage of cells with tubular
peroxisomes (∼3.5-fold increase compared to the control)
(Figure 4A), a similar magnitude of effect as when serum is added
to the MEM/N1 medium. The addition of the PUFA linoleic
acid (LA) [C18:2 (ω-6)] promoted peroxisome elongation, but
less than AA or serum stimulation (∼2.6-fold increase compared
to the control), while oleic acid (OA) [C18:1(ω-9)] also had a
small but significant stimulatory effect on peroxisome elongation
(∼1.4-fold increase compared to the control). However, the
saturated fatty acid palmitic acid (PA) (C16:0) was not able to
induce peroxisome membrane expansion at the concentrations
applied (Figure 4A), even though, as observed for AA, LA,
and OA, the number and size of lipid droplets was increased
in the cells (not shown), indicating that all the fatty acids
are efficiently taken up and stored by the cells. Together, this
suggests a correlation between fatty acid chain length and/or
degree of saturation and their ability to induce peroxisome
elongation. Shorter-chain fatty acids are preferential substrates
for mitochondrial β-oxidation, while the longer-chain fatty acids,
which induce peroxisome elongation, can be β-oxidized in
peroxisomes and/or are involved in the synthesis of cellular
lipid mediators.
PUFAs such as AA and LA can act as PPAR ligands (Varga
et al., 2011), so we next tested the ability of pharmacological
PPAR ligands to induce peroxisome elongation in our
experimental system. Interestingly, they did not induce a
pronounced peroxisome elongation in our experimental
system. While the PPARα agonist Wy-14,643 and the
PPARγ agonist troglitazone did induce some peroxisome
elongation at the higher concentrations tested (Supplementary
Figure 2), this was a significantly smaller effect than the FBS-
induced elongation, suggesting PPAR activation alone is not
sufficient to account for the proliferative effect of serum on
peroxisomes, which is in line with the mild effects described
for peroxisome proliferators on human cells. Furthermore, the
PPARγ antagonist GW9962, which inhibits PPARγ binding
to its binding elements (Liu et al., 2016), caused a small
decrease in peroxisome elongation compared to controls,
but did not occlude the peroxisome elongation/proliferation
induced by serum. This implies that serum contains factors
which can induce peroxisome elongation/proliferation
independently of PPARs.
Apart from fatty acids, the stimulatory effect of serum on
peroxisome dynamics and proliferation may be due to the
involvement of growth factor-dependent pathways, such as
the mTOR pathway. In order to investigate the involvement
of the mTOR pathway in peroxisome elongation/proliferation
in our assay, cells cultured in MEM/N1 medium were pre-
treated with the mTOR inhibitor rapamycin prior to serum
stimulation. Two hours of rapamycin pre-treatment blocked
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FIGURE 1 | Effect of serum on peroxisome morphology/proliferation in HepG2 cells. (A) Representative images of cells cultured in MEM/N1 and cells stimulated with
10% FBS (MEM/N1 + FBS). Cells were processed for immunofluorescence after 24 or 48 h of stimulation and stained with anti-PEX14 antibodies. Bars, 10 µm
(B) Quantitative analysis of peroxisome elongation after 24 h, expressed as percentage of cells exhibiting tubular peroxisomes. Data from 3 independent experiments
(n = 300 cells in each condition); analyzed by two-tailed unpaired t-test. (C) Quantitative analysis of peroxisome number per cell after 48 h. Data from 3 independent
experiments (n = 10 cells for each condition), analyzed by two-tailed unpaired t-test; ***p < 0.001.
peroxisome elongation in response to serum stimulation in a
dose-dependent manner (Figure 4B), supporting our hypothesis
that growth factor-mediated signaling pathways (specifically, the
mTOR pathway) may play a role in the initiation of peroxisome
proliferation during cellular growth.
Differential mRNA Profiles During
Peroxisome Proliferation
Little is known about the regulation of peroxins and peroxisomal
membrane proteins and the relationship between gene expression
and peroxisome proliferation, in particular in humans. The only
peroxin whose expression has so far been linked to peroxisome
proliferation in humans is PEX11 (Schrader et al., 2016). We
therefore set out to profile which peroxisomal genes may be
involved in peroxisomal growth and division by correlating
their time-resolved mRNA expression profiles with distinct
peroxisome proliferation events in our synchronized cell model.
mRNA was extracted at given time points after serum-stimulated
induction of peroxisome proliferation, corresponding to distinct
phases in the elongation and division process (Schrader et al.,
1998a) (Figure 3A) – at 6 h, when peroxisome elongation begins;
at 12 and 24 h when the number of elongated peroxisomes
increases and peaks; and at 48 and 72 h, when division of the
elongated peroxisomes has occurred, and they return to their
spherical shape. qPCR was used to quantify changes in relative
mRNA levels of a number of candidate peroxisomal genes across
these stages of proliferation, normalized to 18S rRNA levels.
We first investigated the mRNA profiles of the three
mammalian isoforms of PEX11 (α, β, and γ) during peroxisome
proliferation, as these proteins are thought to be involved in the
peroxisome growth and division cycle (Figure 3B). Interestingly,
while PEX11β mRNA levels correlated well with the peroxisome
proliferation cycle, PEX11α and PEX11γ did not, with their
mRNA levels declining over time. These findings support
the view that PEX11β is the key PEX11 isoform promoting
peroxisome elongation and subsequent division, with PEX11α
and PEX11γ playing more subtle or different roles.
Interestingly, mRNA levels of the early peroxins PEX3 and
PEX19 were also observed to correlate with the peroxisome
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FIGURE 2 | Effect of fatty acids and rapamycin on peroxisome elongation in HepG2 cells. (A) Quantitative analysis of peroxisome morphology upon stimulation with
50 µM fatty acids in HepG2 cells cultured in MEM/N1 for 24 h. Note the strong stimulatory effect of PUFAs (AA and LA). (B) Quantitative analysis of peroxisome
morphology after treatment of HepG2 cells with rapamycin and subsequent serum stimulation. Data in (A,B) are based on immunofluorescence microscopy using
anti-PEX14 from 3 independent experiments (n = 300 cells in each condition); analyzed by one-way ANOVA with Dunnett’s (A) or Tukey’s (B) post hoc test;
***p < 0.001. AA, arachidonic acid; LA, linoleic acid; OA, oleic acid; PA, palmitic acid.
proliferation cycle, whereas PEX16 remained unchanged and
declined at later time points (Figure 3B). As these early peroxins
are required for the insertion of peroxisomal membrane proteins
including PEX11β, increased mRNA levels of those early peroxins
is consistent with a requirement for PEX11β in proliferation.
Other peroxins such as PEX2, PEX5, PEX10, PEX12, PEX13,
and PEX14, which are involved in peroxisomal matrix protein
import, showed a variety of expression profiles: a minor increase
in mRNA expression after 24 h followed by a decline (PEX10 and
PEX14), a slight decline after 72 h (PEX2) or no change over the
time course (PEX5, PEX12, and PEX13) (Figure 3B). Similarly,
mRNA levels of the AAA-ATPase export complex components
(PEX1, PEX6, and PEX26) did not correlate with the peroxisome
proliferation cycle either, showing a minor increase after 24 h
followed by a decline (PEX1), a decrease in expression after 48 h
which recovers by 72 h (PEX6) and a slight decline after 72 h
(PEX26), respectively.
The mRNA profile of the transcription factors PPARα,
PPARγ1, and PGC1α, which are classically thought to be involved
in the upregulation of peroxisomal matrix protein expression (in
particular β-oxidation enzymes in rodents), did not correlate with
peroxisomal morphology alterations, and expression of those
transcription factors rather declined over time, or remained
constant (PGC1α) (Figure 5A). These findings may indicate that
the observed morphological alterations are independent of those
transcription factors. It has, however, been reported that PPARα
expression is upregulated in HepG2 cells at the mRNA and
protein level following prolonged incubation times in culture
(Stier et al., 1998). Notably, mRNA levels of the transcription
factor PGC1β does seem to correlate with the peroxisome
proliferation cycle, suggesting this could play a role in peroxisome
elongation and/or division. Interestingly, mRNA levels of the
peroxisomal ABC transporter ABCD3 (PMP70) also followed the
morphological changes of peroxisomes, whereas mRNA levels for
ABCD1, the ABC transporter for VLCFA, remained unchanged
(Figure 5B). mRNA levels of ACOX1a and ACOX1b, key enzymes
in the first step of peroxisomal fatty acid β-oxidation, was slightly
reduced over time, while mRNA levels of EHHADH, which
catalyzes the 2nd and 3rd step of peroxisomal β-oxidation, were
upregulated after 24 h, and expression of ACAA1, which catalyzes
the final step, was increased after 12 and 24 h but decreased after
72 h (Figure 5B). mRNA levels for other proteins required for
peroxisomal β-oxidation, such as carnitine metabolism (CROT
and CRAT), also follow different patterns over time, whereas
the peroxisomal membrane protein PMP34 (cofactor transport)
correlated with the peroxisome proliferation cycle. Furthermore,
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FIGURE 3 | Correlation of peroxisome morphology and mRNA abundance profiles of PEX genes in HepG2 cells during a time course. (A) Quantitative analysis of
tubular peroxisomes in HepG2 cells monitored over time in MEM/FBS and processed for immunofluorescence. Data from 4 independent experiments (n = 300 cells
in each condition); analyzed by one-way ANOVA with Dunnett’s post hoc test. (B) qPCR analysis of relative mRNA levels of a set of PEX genes normalized to 18S
rRNA expression over time. Note that PEX11β mRNA levels correlate with the proportion of cells showing tubular peroxisome morphology, emphasizing its role in
peroxisome elongation and division. In contrast, PEX11α mRNA levels do not correlate with changes in peroxisome morphology. Data from 4 independent
experiments; analyzed by one-way ANOVA with Dunnett’s post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 4 | mRNA abundance profiles of peroxisomal transcription factors/co-factors (A) and peroxisomal genes associated with fatty acid beta-oxidation (B) in
HepG2 cells during a time course. qPCR analysis of relative mRNA levels of the indicated genes, normalized to 18S rRNA expression over time. Data from 4
independent experiments; analyzed by one-way ANOVA with Dunnett’s post hoc test; *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 5 | The human PEX11 isoforms affect peroxisome morphology differently. (A) Quantitative analysis of peroxisome morphologies in cells expressing different
human PEX11 isoforms. COS-7 cells were transfected with Myc-PEX11α, Myc-PEX11β, or Myc-PEX11γ, processed for immunofluorescence using anti-Myc and
anti-PEX14 antibodies at the indicated time points after transfection, and analyzed by microscopy. Note the prominent effect of Myc-PEX11β and Myc-PEX11γ on
peroxisome elongation/division, in contrast to Myc-PEX11α expression, which is similar to mock-transfected controls (Con). Data from 4 independent experiments;
analyzed by one-way ANOVA with Dunnett’s post hoc test for each time point; *p < 0.05, ***p < 0.001. (B) HeLa PEX11 KO cells and controls, and
PEX11β-deficient fibroblasts were processed for immunofluorescence microscopy using antibodies against PEX14. Note the reduced number and elongation of
peroxisomes in the PEX11β-deficient cells. Bars, 10 µm.
mRNA levels of peroxisomal enzymes involved in plasmalogen
synthesis showed distinct profiles, either increasing (AGPS and
GNPAT) or decreasing (FAR1) at later time points (Figure 5B).
Together this suggests that, in some cases, peroxisomal genes that
perform similar functions (e.g., enzymes involved in β-oxidation
or plasmalogen synthesis) may be independently regulated
during proliferation.
The Mammalian PEX11 Isoforms Differ in
Their Membrane Elongation-Inducing
Properties
Our results from the mRNA profiling during peroxisome
proliferation suggested that the three human PEX11 isoforms
may play different roles in the regulation of peroxisome
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FIGURE 6 | Venn diagram of shared transcription factor binding sites within
the promoter regions of human PEX11 isoforms. Potential binding sites for
SMAD2/3 (activated by the TGFβ pathway) in PEX11γ and PEX11β were
predicted to be located in a transcriptionally active area according to histone
marks.
dynamics. In order to compare the functional effects of these
isoforms on peroxisome morphology, COS-7 cells cultured in
serum-containing media (to promote peroxisome growth and
division) were transfected with Myc-PEX11α, Myc-PEX11β, or
Myc-PEX11γ, processed for immunofluorescence after 5–72 h
using anti-Myc and anti-PEX14 antibodies, and analyzed
(Figure 6A). Quantification of peroxisome morphology revealed
that overexpression of both Myc-PEX11β and Myc-PEX11γ had
already induced the formation of tubular peroxisomes just 5 h
after transfection. The number of cells with tubular peroxisomes
declined over time, likely due to division of elongated
peroxisomes into spherical organelles. In contrast, expression of
Myc-PEX11α did not induce peroxisome elongation, and values
were similar to controls confirming previous studies in both
HepG2 and COS-7 cells (Schrader et al., 1998b; Delille et al.,
2010). These findings indicate that the PEX11 isoforms affect
peroxisome morphology differently, with β and γ being capable
of inducing peroxisome elongation, whereas α cannot.
We also analyzed peroxisome morphology in HeLa CRISPR
knock out (KO) cells lacking PEX11α, PEX11β, or PEX11γ,
cultured in serum-containing media. Immunofluorescence
microscopy using anti-PEX14 antibodies revealed a spherical
peroxisome morphology in PEX11α and PEX11γ KO cells, which
was comparable to controls (Figure 6B). In contrast, peroxisomes
in PEX11β KO cells were reduced in number and showed a rod-
shaped, slightly elongated morphology (Figure 6B). A similar
peroxisome morphology was observed in skin fibroblasts from
patients with a loss of PEX11β (Figure 6B) (Ebberink et al., 2012).
At first glance, the slightly elongated peroxisome morphology in
PEX11β-deficient cells may contradict the proposed function of
PEX11β as a driver of membrane elongation. However, PEX11β
also plays a role in peroxisome division as it acts as a GTPase
activating protein (GAP) on the fission GTPase DRP1 (Williams
et al., 2015). We suggest that as a consequence of this GAP
function, peroxisome division is reduced in the absence of
PEX11β leading to a slight elongation of peroxisomes, perhaps
mediated by PEX11γ, which also has membrane elongating
properties (Figure 6A) and can partially complement PEX11β
(Ebberink et al., 2012).
Promoter Analysis of the PEX11
Isoforms Suggests They Are
Independently Regulated
Since the mRNA profiles of the three PEX11 isoforms differed
during the peroxisome proliferation/division cycle, we set out to
identify candidate factors leading to this differential regulation.
A comparison of the promoter regions of all three human
PEX11 genes revealed that PEX11β and PEX11γ share four
putative transcription factor binding sites for SMAD2/3 (Small
worm phenotype/Mothers Against Decapentaplegic homolog
2/3), ATF4 (Activating Transcription Factor 4), SOX10 (Sex-
determining Region Y-related High Mobility Group-box 10)
and PPARγ. In contrast, no transcription factor binding sites
are shared between PEX11β and PEX11α, while PEX11α and
PEX11γ only share one binding site (for PPARα) (Figure 7).
These findings indicate that PEX11β and PEX11α are likely
to be differently regulated at a transcriptional level and
further support our notion that both proteins fulfill different
functions at peroxisomes.
The Canonical TGFβ Pathway Is Involved
in Peroxisome Proliferation in HepG2
Cells
One of the key activators of SMAD2/3 is transforming growth
factor beta (TGFβ), via the canonical TGFβ signaling pathway.
We chose to focus our subsequent studies on SMAD2/3-mediated
regulation of PEX11β and the possible link between TGFβ
signaling and peroxisome proliferation, as a proof-of-principle
of our predictive promoter analysis. This was selected because
of: (i) the functional role of PEX11β in peroxisome elongation
and division (Figure 6); (ii) the high probability prediction of
a SMAD2/3 binding site in the promoter region of PEX11β
(Supplementary Table 6), and (iii) the ability of TGFβ to
activate mTOR, a driver of peroxisome proliferation (Figure 4B),
which together suggested that expression of PEX11β, and thus
peroxisome proliferation, might be linked to TGFβ signaling.
First, we tested whether TGFβ could induce peroxisome
elongation and proliferation in our cell-based model. HepG2
cells cultured in MEM/N1 were mock treated or treated with
2 ng/ml recombinant TGFβ for 24 h prior to fixation and PEX14
immunofluorescence (Figure 2). Recombinant TGFβ activates
Type I and, indirectly, Type II TGFβ receptors on the cell
surface, resulting in phosphorylation of the SMAD2/3 complex
and its translocation to the nucleus where it can modulate
transcription of target genes (Dituri et al., 2013). Whereas
control cells showed overwhelmingly spherical peroxisomes,
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FIGURE 7 | TGFβ increases peroxisome elongation and number in HepG2 cells. (A) HepG2 cells were cultured in MEM/N1, treated with 10% FBS, or TGFβ
(2 ng/ml) (with or without inhibitors LY2109761 or SB431542) or mock treated and processed for immunofluorescence after 24 h after treatment using anti-PEX14
antibodies. Representative images and quantitative analysis of peroxisome morphology (elongation) for the conditions described are shown. Data from 3
independent experiments (n = 300 cells for each condition); analyzed by one-way ANOVA with Tukey’s post hoc test; ***p < 0.001. Bars, 10 µm. (B) HepG2 cells
were cultured in MEM/N1 for 6 h prior to the addition of TGFβ (2 ng/ml) or 10% FBS, and processed for immunofluorescence after 6 h (‘before’ treatment) and 48 h
after treatment as described in (A). Representative images and quantitative analysis of peroxisome number/cell before and 48 h are shown. Data from 3 independent
experiments (n = 10 cells for each condition); analyzed by one-way ANOVA with Tukey’s post hoc test; ***p < 0.001. Bars, 10 µm.
addition of TGFβ resulted in a pronounced elongation of
peroxisomes, a pre-requisite of peroxisomal growth and division
(Figure 2A). To validate that the effect was specific to the
SMAD-mediated TGFβ pathway, we used specific chemical
inhibitors which block the TGFβ signaling pathway. SB431542
selectively inhibits Type I TGFβ receptors by suppressing
SMAD3 phosphorylation, whereas LY2109761 inhibits both Type
I and II receptors, resulting in reduced phosphorylation of
SMAD2 (Dituri et al., 2013). Pre-treatment of HepG2 cells
with either inhibitor for 2 h before adding recombinant TGFβ
reduced peroxisome elongation significantly when compared
to TGFβ-treated controls (Figure 2A) indicating a specific
TGFβ-mediated response. Furthermore, consistent with the
effect of serum stimulation, the number of peroxisomes in
TGFβ-treated cells was significantly increased when compared
to unstimulated controls (Figure 2B). 48 h TGFβ treatment
resulted in an over two-fold increase in peroxisome numbers
compared to untreated cells cultured for the same amount of
time, which is indicative of accelerated peroxisome proliferation.
Overall, these findings support a role for TGFβ signaling in
peroxisome proliferation, potentially via SMAD2/3 binding to the
PEX11β promoter.
To verify that transcription of PEX11β can be regulated by
TGFβ in a SMAD-dependent manner, we transfected HepG2
cells with constructs consisting of a firefly luciferase reporter
gene under the control of the PEX11β promoter, and assayed
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the effect of TGFβ on luminescence as a result of firefly
luciferase expression (Figure 8). TGFβ treatment dramatically
increased the expression of firefly luciferase driven by the
wild type PEX11β promoter (or a control promoter with
an optimized SMAD2/3 binding site, ‘SMAD’), relative to a
constitutively expressed, TK promoter-driven Renilla luciferase
as an internal control. However, mutating the putative SMAD2/3
binding site in the PEX11β promoter (‘mut’) prevented the
TGFβ-dependent increase in reporter expression (Figure 8).
These findings indicate that the SMAD2/3 binding site
within the PEX11β promoter is functional, and that PEX11β
transcription is positively regulated by TGFβ signaling via its
SMAD2/3 binding site.
DISCUSSION
In this study, we used the well-differentiated human
hepatoblastoma cell line HepG2 as a model system to assess the
ability of different stimuli to induce peroxisome proliferation.
The peroxisomal compartment in HepG2 cells is very dynamic,
displaying high plasticity including the presence of elongated
peroxisomes (Schrader et al., 1996; Grabenbauer et al., 2000).
These elongated peroxisomes form by membrane expansion as a
pre-requisite of peroxisome division and can be observed during
rapid cellular growth, for example after hepatectomy (Yamamoto
and Fahimi, 1987b) or in cultured mammalian cells (including
COS-7 cells) (Schrader et al., 1996, 1998a; Duclos et al., 1997).
Stimulation of cultured cells with defined growth factors, fatty
acids or free radicals promotes peroxisome elongation (Schrader
et al., 1998a, 1999) as does depolymerisation of microtubules
(Schrader et al., 1996; Passmore et al., 2017), suggesting the
involvement of intracellular signaling in peroxisome elongation.
Motor-driven pulling forces, e.g., mediated by the kinesin-
adaptor Miro1 along microtubules, can also contribute to
peroxisomal membrane expansion (Castro et al., 2018) as
well as inhibition of the peroxisomal division machinery
(Koch et al., 2003; Gandre-Babbe and van der Bliek, 2008;
Passmore et al., 2020) and tethering of peroxisomes to the ER
(Costello et al., 2017).
We show here that peroxisome membrane
expansion/elongation in HepG2 cells depends on serum/growth
factors, and can be inhibited by rapamycin, an inhibitor of the
mTOR pathway, the main growth factor-dependent pathway in
mammalian cells (Wullschleger et al., 2006). Indeed, the mTOR
pathway has recently been linked to peroxisome homeostasis
and signaling (Zhang et al., 2013, 2015). Notably, the PPARγ
antagonist GW9962 did not prevent the induction of peroxisome
elongation by serum, while the PPARα agonist Wy-14,643
and the PPARγ ligand troglitazone only had a relatively small
stimulatory effect on peroxisome elongation, and to a lower
extent than serum addition. These observations are in line
with earlier studies (Sher et al., 1993; Stangl et al., 1995;
Duclos et al., 1997; Schrader et al., 1998b; Hsu et al., 2001;
Lawrence et al., 2001; Bagattin et al., 2010) and point to the
involvement of PPAR-independent pathways in peroxisome
elongation/proliferation in humans. In a high-content screen
probing more than 15,000 drugs, 10 compounds were reported
to induce peroxisome proliferation in HepG2 cells, which appear
to be only mildly sensitive to PPARα-mediated peroxisome
proliferation (Sexton et al., 2010).
A stimulatory effect of PUFAs, especially AA [C20:4 (ω-6)]
on peroxisomal membrane expansion confirms earlier studies
(Schrader et al., 1998a). PA (C16:0), a preferential substrate
for mitochondrial β-oxidation, was not effective in inducing
elongation, supporting specificity for longer-chain/unsaturated
fatty acids, which link to the synthesis of cellular lipid mediators.
AA is the substrate for the synthesis of prostaglandins and
leukotrienes. As peroxisomes are involved in the degradation of
prostaglandins (Diczfalusy and Alexson, 1988; Schepers et al.,
1988) and leukotrienes (Jedlitschky et al., 1991), peroxisome
elongation/proliferation may help to balance intracellular levels
of these eicosanoids. Furthermore, other PUFAs such as
DHA [C22:6(n−3)] have previously been shown to mediate
peroxisome elongation and division/proliferation (Itoyama et al.,
2012). While PUFAs, including DHA, are well-characterized
ligands of PPARα (Krey et al., 1997), DHA-induced peroxisomal
proliferation has been shown to be independent of PPARα
activation, but dependent on PEX11β and peroxisome division
factors (Itoyama et al., 2012).
In line with this, PEX11β mRNA levels correlated well with
peroxisome elongation and subsequent division/proliferation.
PEX14 mRNA levels were also slightly upregulated after
24 h in culture, when peroxisomes were also most elongated.
Besides a role in matrix protein import, PEX14 has also been
suggested to function as a microtubule docking factor stabilizing
elongated peroxisomes, which may explain its induction during
proliferation (Bharti et al., 2011; Theiss et al., 2012; Castro
et al., 2018; Passmore et al., 2020). mRNA levels of the
peroxisomal ABC transporter ABCD3 (PMP70) correlated with
the peroxisome proliferation cycle in line with previous studies
(Schrader et al., 1998a). mRNA levels for the transcription factor
PPARα or ACOX1, a key enzyme in peroxisomal β-oxidation,
did not correlate with the peroxisome proliferation cycle, which
is perhaps surprising, as enzyme expression may be expected to
rise in line with the increase in peroxisome number to maintain
normal metabolism. However, mRNA and protein levels of
PPARα and branched-chain ACOX2 have been previously shown
to only be markedly elevated at the later phases of long-
term culture and differentiation of HepG2 cells, suggesting that
peroxisome proliferation (investigated here) and peroxisome
maturation, characterized by a metabolically-active phenotype
once cells reach confluency, may be two distinct and differentially
regulated processes (Stier et al., 1998). PGC1α mRNA levels
are also reported to increase after 3 days, and may link to
an (differentiation-dependent) induction of peroxisomal activity
(Bagattin et al., 2010; Huang et al., 2017).
We focussed on the function and regulation of the PEX11
proteins, which are supposed to be key regulators of peroxisome
proliferation, although the functions of the different PEX11
isoforms in peroxisome proliferation are still controversial.
They have been suggested to cooperate in the coordination of
peroxisomal growth and division (Koch and Brocard, 2012), but
functions in fatty acid oxidation, transport processes, organelle
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FIGURE 8 | TGFβ activates PEX11β expression by direct binding of the SMAD2/3 transcription factor to the PEX11β promoter. Luciferase reporter assays in HepG2
cells transfected with a Firefly-Luc reporter under the control of a SMAD2/3 motif-containing promoter (‘SMAD’); or PEX11β wild type (‘WT’) or SMAD2/3 mutant
(‘mut’) promoter. As a control, a promoter-less Firefly-Luc vector was used. Cells were treated with TGFβ (2 ng/ml) or left untreated. (A) Schematic of the reporter
vectors used. The potential SMAD2/3 binding motif (underlined) in the PEX11β promoter and the deleted base pairs are indicated. pRL-TK construct with thymidine
kinase promoter upstream of Renilla luciferase was used as an internal control in all the experiments. (B) Quantitative analysis of the effect of TGFβ on promoter
activity. Firefly luciferase activity (FLuc) was first normalized to Renilla luciferase activity (RLuc) in each condition. Fold increase in response to TGFβ was then
calculated by normalizing the relative luminometer unit values for each construct in the presence of TGFβ to the value without TGFβ. Data from 3 independent
experiments; analyzed by one-way ANOVA with Tukey’s post hoc test; ns non-significant, ***p < 0.001.
interplay and membrane contacts have also been reported (van
Roermund et al., 2000; Dulermo et al., 2015; Mattiazzi Ušaj et al.,
2015; Mindthoff et al., 2016; Kustatscher et al., 2019; Wu et al.,
2020).
Our data reveal that PEX11β and PEX11α are likely to
be differently regulated as different transcription factors are
predicted to control their expression. Additionally, in contrast
to PEX11β, PEX11α mRNA levels did not follow the changes
in peroxisome morphology in HepG2 cells. Furthermore,
expression of PEX11α did not induce peroxisome membrane
expansion, which is consistent with previous studies (Schrader
et al., 1998b; Delille et al., 2010). PEX11α cannot complement
loss of PEX11β (Ebberink et al., 2012), and despite their similar
membrane topology, both proteins show different sensitivity to
Triton-X 100 pointing to different functions and biochemical
properties within the peroxisomal membrane (Schrader et al.,
2012a). Patients suffering from PEX11β deficiency have been
identified (Ebberink et al., 2012; Taylor et al., 2017; Tian et al.,
2019), whereas patients with a defect in PEX11α function have
not yet been diagnosed. In line with this, knockout of PEX11β
in mice is lethal, whereas PEX11α KO mice appear healthy
(Li et al., 2002a,b). However, feeding of PEX11α KO mice
with a high-fat diet resulted in impaired physical activity and
energy expenditure, decreased fatty acid β-oxidation, increased
de novo lipogenesis as well as dyslipidaemia and obesity (Chen
et al., 2019). Overall, these findings highlight that PEX11α and
PEX11β have different functions, and may support a role for
PEX11α in peroxisomal fatty acid metabolism rather than in
peroxisome proliferation.
We confirmed that the identified putative SMAD2/3
binding site in the promoter region of PEX11β is functional
and TGFβ-responsive, and could potentially link peroxisome
proliferation to the canonical, SMAD-dependent TGFβ
signaling pathway in HepG2 cells. A stimulatory effect of
TGFβ on peroxisome elongation, albeit less prominent
due to altered experimental conditions, was observed
in a previous study (Schrader et al., 1998a). Other genes
containing putative SMAD2/3 binding sites include PEX11γ,
FIS1, PEX13 and PEX14 (Supplementary Table 6) further
indicating the potential involvement of this pathway in
the regulation of genes involved in peroxisome dynamics,
and these genes may therefore also contribute to the
TGFβ-induced peroxisome proliferation, along with
PEX11β. Previous work has demonstrated a reduction
in PEX13 and PEX14 expression in fibroblasts following
TGFβ stimulation (Oruqaj et al., 2015), which is perhaps
surprising given our data suggests TGFβ promotes peroxisome
proliferation, and we find PEX13 mRNA stays the same, while
PEX14 mRNA increases, during FBS-induced peroxisome
proliferation (Figure 3). This could be a result of tissue-
specific differences in the TGFβ-dependent regulation of
peroxisome proliferation, or differences in the regulation of
PEX13 and PEX14 by serum factors as opposed/in addition
to TGFβ.
The TGFβ pathway is involved in the regulation of
cellular proliferation, differentiation, embryogenesis, apoptosis,
inflammation, immunity and cancer pathways (Massagué, 2012).
TGFβ is also a key regulator of liver physiology and pathology.
It contributes to hepatocyte proliferation and differentiation, but
also to all stages of disease progression, from initial liver injury
through inflammation and fibrosis to cirrhosis and hepatocellular
carcinoma (Fabregat et al., 2016). HepG2 cells have been shown
Frontiers in Cell and Developmental Biology | www.frontiersin.org 14 October 2020 | Volume 8 | Article 577637
fcell-08-577637 October 18, 2020 Time: 19:3 # 15
Azadi et al. Regulation of Human Peroxisome Dynamics
to express TGFβ and to respond to TGFβ treatment or silencing
of TGFβ with alterations in cell growth, apoptosis and the
cell cycle (Wang et al., 2017). We assume that TGFβ signaling
in our experimental system contributes to the proliferation
and/or differentiation of HepG2 cells as peroxisome elongation
is a hallmark of cell growth and proliferation (Schrader
et al., 1999). Interestingly, elongated and tubular or constricted
peroxisomes were also observed after partial hepatectomy in
rat liver (Yamamoto and Fahimi, 1987a). These heterogenous
peroxisome morphologies were interpreted as an indicator of
peroxisome proliferation by elongation/growth and division
under conditions of cellular growth and proliferation (Schrader
and Fahimi, 2008). TGFβ has a crucial role in hepatocytes
in vivo, being critical for the control of liver mass (Karkampouna
et al., 2012). The TGFβ pathway has activator and repressor
effects on other pathways such as cell growth, so balanced TGFβ
signaling in terms of both dosage and spatiotemporal activity
is crucial to control hepatic gene expression. TGFβ acts in the
process of differentiation of hepatoblasts to hepatocytes during
liver regeneration after partial hepatectomy (Karkampouna et al.,
2012). The TGFβ pathway is required at different stages of
the process, to allow hepatocyte proliferation at the inductive
phase followed by an efficient termination of the regenerative
response afterward.
Since HepG2 cells are hepatoblastoma cells, which can
differentiate in culture and form bile canaliculi-like structures
(Bokhari et al., 2007), we propose that, similar to regenerating
liver, TGFβ induces peroxisome proliferation in HepG2 cells
under proliferative culture conditions, possibly via upregulation
of PEX11β, a key regulator of peroxisomal growth and
multiplication. Under standard culture conditions, peroxisome
elongation has a maximum after 24–48 h, before the elongated
peroxisomes divide resulting in the formation of numerous
spherical peroxisomes. Peroxisomes do not massively elongate
at later time points in culture, when the cells are more
confluent, and therefore growing more slowly (Schrader et al.,
1998a). Ultrastructural studies have shown that at prolonged
culture the peroxisomes in HepG2 cells are larger and
form small clusters of organelles, possibly changing from a
proliferative to a metabolic state (Grabenbauer et al., 2000).
As PEX11β mediates peroxisome elongation and proliferation,
it represents an ideal target to adapt peroxisome number
and function according to cellular needs. TGFβ signaling
may foster peroxisome proliferation in an inductive phase of
HepG2/hepatocyte proliferation and differentiation, but may
also reduce proliferation of peroxisomes afterward, when the
inductive stage is completed, and cell growth needs to be
terminated. As TGFβ signaling is complex, it is likely that other,
non-canonical signaling pathways as well as TGFβ secretion,
the concentration of active TGFβ, and the amount of TGFβ
receptors and spatiotemporal activity, contribute to the overall
cellular response. Additionally, PEX11β expression is likely to
be subject to other levels of regulation, such as translational
control or alterations in protein stability, localization or activity,
that coordinate to fine-tune peroxisome proliferation in response
to various conditions, which is an interesting avenue for
future investigation.
CONCLUSION
We reveal a new TGFβ-dependent signaling pathway controlling
peroxisome proliferation which may act by regulating PEX11β
gene expression. This opens a possibility for therapeutic
approaches controlling regulation of PEX11β in patients where
peroxisome abundance/activity is reduced.
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